UBS Group
RARE icon

UBS Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

UBS Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,700
Closed -$379K – 8583
2015
Q2 		$379K Buy
+3,700
New +$287K ﹤0.01% 4350

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

UBS Group's RARE Position: Q1 2026 in Review

UBS Group increased its Ultragenyx Pharmaceutical (RARE) stake by 25% in Q1 2026, buying an estimated $3.69M and bringing the position to 832,740 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2738.

UBS Group first reported a position in RARE in Q4 2014 and has held it in 46 quarters since. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • UBS Group held 832,740 shares of Ultragenyx Pharmaceutical worth $17.4M as of Q1 2026.
  • UBS Group bought 163,929 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.69M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2738 holding.
  • UBS Group first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 46 quarters since.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.